Spots Global Cancer Trial Database for optional endocrine therapy of investigator's choice
Every month we try and update this database with for optional endocrine therapy of investigator's choice cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | NCT05894239 | Metastatic Brea... | Inavolisib Phesgo Placebo Taxane-based Ch... Optional Endocr... | 18 Years - | Hoffmann-La Roche |